Sodium Selenite in Metabolic Oncology - A Compound Named After the Moon
The story of sodium selenite begins not in an oncology clinic, but in a Swedish sulphuric-acid factory more than two centuries ago.
In 1817, the chemist Jöns Jacob Berzelius was investigating an unusual reddish deposit that had formed during acid production. He initially believed it contained tellurium, an element whose name came from the Latin word for Earth. Closer examination revealed something entirely new.
Berzelius named the newly discovered element selenium, after Selene, the Greek goddess of the Moon. Tellurium represented Earth, so its closely related chemical neighbour was given a name connected to the Moon.
For much of the following century, selenium was known mainly for its industrial uses and its potential toxicity. It was used in glassmaking, pigments, photography and early electronic devices. Farmers also learned that animals grazing on plants grown in selenium-rich soils could become seriously unwell. Selenium initially appeared to be more poison than nutrient.
The scientific story changed during the twentieth century when researchers discovered that selenium is also essential to human life. In small amounts, the body uses it to produce specialised proteins involved in thyroid function, immunity, antioxidant protection and the management of oxidation within cells.
Selenium therefore developed an unusual biological reputation. Too little can be harmful. An appropriate amount is essential. Too much can become toxic.
This is one reason selenium can be so confusing in cancer discussions. It is often spoken about as though it were one substance with one predictable effect. In reality, its behaviour depends upon its chemical form, the amount used, how it enters the body and what happens to it once it reaches a cell.
Selenium found naturally in food is not identical to selenomethionine, selenium-enriched yeast or sodium selenite. Although each contains selenium, they are handled differently by the body and may produce very different biological effects.
Sodium selenite is an inorganic selenium salt. It is more chemically reactive than many of the selenium forms commonly used for nutritional support. Once inside a cell, it can interact with protective molecules such as glutathione and thioredoxin. During these reactions, it may contribute to the creation of reactive oxygen species and place additional pressure on the cell’s ability to remain chemically stable.
This is the first essential point to understand: the interest in sodium selenite within metabolic oncology does not come simply from selenium being an essential mineral. It comes from the unusual behaviour of this particular form of selenium.
Cancer’s Difficult Relationship With Oxidative Stress
To appreciate why sodium selenite has attracted interest in cancer research, we first need to understand the difficult relationship cancer cells have with oxidative stress.
Every cell produces reactive oxygen species as part of normal life. These are highly reactive molecules created during energy production, immune activity and many ordinary chemical reactions. Superoxide and hydrogen peroxide are two common examples.
Reactive oxygen species are often described simply as harmful free radicals, but that is only part of the story. At controlled levels, they also work as signals. They help cells communicate, adapt, grow and respond to their environment.
Cancer cells often produce more of these reactive molecules than healthy cells. This can happen because they are growing rapidly, producing large amounts of new cellular material, processing nutrients at an unusual rate and operating with altered mitochondria.
Some of this oxidative activity helps the cancer. It can support growth signals, blood-vessel formation, adaptation and movement into surrounding tissues.
The problem is that the same reactive molecules can become destructive when their levels rise too far. Excessive oxidative stress can damage DNA, proteins, cell membranes and mitochondria. If enough damage accumulates, the cell may no longer be able to repair itself or remain alive.
Cancer cells therefore live in a precarious relationship with oxidative stress. They may benefit from some of it, but too much can push them over the edge.
To survive this balancing act, many cancers strengthen their antioxidant defences. They increase their production of protective molecules and enzymes that remove reactive oxygen species and repair oxidative damage. Glutathione and thioredoxin are two of the most important systems involved.
The cancer cell can be imagined as a factory filled with machinery running unusually hot. The heat helps the factory produce quickly, but it also creates a constant fire risk. The antioxidant systems are the cooling units, sprinklers and emergency crews preventing the building from burning down.
This creates a possible therapeutic opportunity.
A healthy cell may have more room to cope with an additional oxidative challenge. A cancer cell already operating close to its limit may have far less room to move. Increasing oxidative pressure, weakening antioxidant protection or doing both together may push the cancer cell beyond its ability to recover.
This is where sodium selenite becomes particularly interesting.
The Double Edge of Sodium Selenite
Sodium selenite appears to work through two closely connected actions. It may help increase oxidative stress while also placing pressure on the systems needed to control that stress.
The first edge is its ability to behave as a pro-oxidant.
A pro-oxidant is a substance that encourages oxidation rather than preventing it. This does not mean sodium selenite simply carries damaging molecules into a cell. Instead, as the compound is processed, it enters into chemical reactions that may generate reactive oxygen species from within.
Sodium selenite can react with glutathione and other sulphur-containing molecules inside the cell. Through a series of steps, this may lead to the formation of reactive selenium compounds and superoxide.
In effect, the cell’s own machinery helps activate sodium selenite’s pro-oxidant behaviour.
Research in prostate-cancer cells found that sodium selenite increased superoxide within the mitochondria, disturbed the mitochondrial membrane and activated a pathway leading to cell death. When researchers strengthened the cells’ mitochondrial antioxidant protection, those cells became more resistant to sodium selenite. This supported the idea that oxidative damage inside the mitochondria was central to its effect.
Similar findings have been reported in liver-cancer and leukaemia cells, where increased reactive oxygen species were followed by mitochondrial injury and cancer-cell death.
The second edge is sodium selenite’s effect on antioxidant protection.
Cancer cells frequently depend heavily on glutathione. Glutathione helps neutralise harmful molecules, protect membranes and proteins, and support the enzymes responsible for clearing oxidative damage. Many cancers maintain high glutathione levels because doing so helps them survive their own demanding metabolism and recover from the stress created by treatment.
Sodium selenite has a particularly interesting relationship with glutathione. Glutathione helps process the compound, but in doing so it may contribute to the chemical reactions that create oxidative stress. At the same time, glutathione is needed to defend the cell against the very stress being produced.
It is a little like asking the same worker to operate the furnace and extinguish any fires that follow. For a while, the arrangement may remain manageable. But as the demands increase, the worker begins using up the equipment and energy needed to keep the building safe.
Research has shown that sodium selenite can reduce the amount of glutathione remaining in its protective form. As this happens, the cancer cell may be left facing two connected problems: more oxidative stress is being created, while fewer antioxidant resources are available to control it.
The thioredoxin system is another important part of this story. Thioredoxin helps repair damaged proteins, supports DNA production and protects cells from oxidative stress. Many cancers increase thioredoxin activity because it helps them grow, adapt and resist treatment.
Sodium selenite can interact with this system and place further demand upon the resources needed to maintain it. The science is complicated, and it would be inaccurate to say that sodium selenite simply switches thioredoxin off. A better way to understand it is that the compound draws the cancer cell’s protective systems into a series of reactions that may progressively become harder to control.
This is what makes sodium selenite unusual.
It may not only create more oxidative pressure. It may also make it harder for the cancer cell to defend itself against that pressure.
That is its defining double edge:
more oxidative stress, with less capacity to contain it.
Mitochondria and the Decision Between Survival and Death
Mitochondria are commonly described as the power stations of the cell because they help produce energy. However, they also take part in metabolism, stress responses and the decision about whether a badly damaged cell should survive or die.
When sodium selenite increases oxidative stress inside mitochondria, the delicate electrical balance across their membrane may begin to fail. This balance is essential for normal energy production.
If the mitochondrial membrane becomes unstable, several things may happen. Energy production can decline, more reactive oxygen species may escape, and signals that trigger cell death may be released into the surrounding cell.
One of the forms of cell death linked with sodium selenite is apoptosis.
Apoptosis is an organised self-destruct programme. Healthy cells use it when they become too damaged to function safely. Rather than breaking apart chaotically, the cell shuts itself down in a controlled way and is removed.
Cancer cells often develop ways to resist apoptosis. They continue growing even when their DNA is damaged and a healthy cell would have accepted that it was time to step aside.
In laboratory studies, sodium selenite has restored some of this pressure towards cell death. Increased oxidative stress can damage the mitochondria and release signals that activate apoptosis. This has been observed in several cancer types, although the exact pathway differs from one model to another.
This variation may be important. Sodium selenite does not appear to depend on a single receptor or one narrow pathway. Instead, it may create enough disturbance across several systems that the cancer cell loses its ability to maintain control.
More recent research has also connected sodium selenite with ferroptosis.
Ferroptosis is a form of regulated cell death caused by iron-dependent damage to the fats within cell membranes. These fats are vulnerable to oxidation. If the damage becomes too extensive and the cell cannot repair it, the membrane begins to fail.
Cancer cells protect themselves from ferroptosis through glutathione and an enzyme called GPX4. GPX4 helps remove damaging compounds from cell membranes before they can cause widespread destruction.
A 2020 study found that sodium selenite could trigger ferroptosis in several human cancer-cell models. The process involved superoxide, iron and the oxidation of fats within the cell membrane.
There is an interesting twist here. Selenium is needed by the body to produce GPX4, the enzyme that helps protect against ferroptosis. At ordinary nutritional levels, selenium may therefore strengthen this protective system. Yet pharmacological sodium selenite may create enough oxidative stress to overwhelm it.
This is not truly a contradiction. It is another reminder that the form of selenium and the context in which it is used determine what it does.
At one level, selenium can support antioxidant protection. In another form and at a different level, sodium selenite may help overcome that protection.
Laboratory research has also connected sodium selenite with stress inside the part of the cell responsible for folding proteins, disruption of the cell-division cycle, damage to DNA and other forms of cell death.
These mechanisms have not all been proven to occur in the same way in the human body. What they demonstrate is that sodium selenite is not merely a nutritional antioxidant. It is a redox-active compound capable of creating several forms of cellular crisis when a susceptible cancer cell loses control of its internal balance.
Where Sodium Selenite Fits Within Press–Pulse
A Press–Pulse strategy recognises that different interventions have different jobs.
A press applies steady, ongoing pressure to the conditions supporting cancer. This may involve reducing excessive insulin signalling, improving metabolic health, limiting access to particular fuels, addressing chronic inflammation, supporting circadian rhythm or making it harder for cancer cells to switch between energy sources.
A pulse is more concentrated. It creates a shorter period of increased stress intended to push the cancer cell beyond its ability to adapt.
Sodium selenite fits most naturally on the pulse side of this approach.
Correcting selenium deficiency is a nutritional consideration, but that is not the same as using sodium selenite for its possible anti-cancer effects. In the context of a metabolic oncology strategy, the interest lies in its ability to increase oxidative pressure, disturb antioxidant protection, impair mitochondria and lower the threshold for cancer-cell death.
These are not gentle background actions. They are stress-amplifying actions.
Sodium selenite may also function as a pulse sensitiser. A sensitiser is not necessarily expected to do all the work by itself. Its purpose may be to make the cancer cell less able to tolerate another treatment.
This is an important distinction. Some interventions are intended to directly damage cancer cells. Others reduce the availability of a fuel, interfere with a growth signal or weaken a repair pathway. A sensitiser may have its greatest value when placed beside the treatment it is intended to strengthen.
Sodium selenite may help weaken the cancer cell’s redox defences before or alongside treatments that create oxidative or DNA damage. What might otherwise have been a manageable stress may then become more difficult for the cancer cell to survive.
The press can be imagined as gradually narrowing the cancer cell’s options. The pulse creates a more immediate crisis. Sodium selenite may help ensure that when this crisis arrives, some of the cancer cell’s emergency systems are already struggling.
This is also why timing is so important.
An intervention that increases oxidative stress may be useful in one part of a strategy and poorly placed in another. A form of selenium used to support antioxidant enzymes is biologically different from sodium selenite being considered as a pro-oxidant pulse. Calling them both “selenium” without explaining the difference can obscure the entire purpose of the intervention.
Sodium Selenite Alongside Radiotherapy and Chemotherapy
Radiotherapy damages cancer cells partly by generating reactive oxygen species and causing breaks in DNA. Cancer cells may survive a portion of this damage if their antioxidant and repair systems are strong enough to restore stability.
This has led researchers to explore sodium selenite as a possible radiosensitiser.
The reasoning is straightforward. Radiotherapy creates oxidative and genetic damage. Sodium selenite may add further oxidative pressure while placing greater demand on the systems the cancer cell needs for recovery. Together, these effects may make the damage harder to repair.
A phase I study investigated sodium selenite given before palliative radiotherapy in people with metastatic cancer. The main purpose was to assess safety and tolerability rather than prove that sodium selenite improved the effectiveness of radiotherapy.
The combination could be administered within the research protocol, and some early signs of disease stability and symptom improvement were reported. However, the study was small, had no comparison group and could not determine whether sodium selenite improved survival or tumour control.
The responsible conclusion is not that sodium selenite has been proven to improve radiotherapy. It is that the combination has a reasonable biological basis and has moved into early human investigation.
A similar argument applies to chemotherapy.
Some chemotherapy medicines create oxidative stress. Others damage DNA, interfere with cell division or disrupt important structures within the cell. These effects may leave the cancer cell increasingly dependent on glutathione, thioredoxin and other repair systems.
Laboratory and animal studies have investigated sodium selenite alongside several anti-cancer medicines. In pancreatic-cancer models, sodium selenite showed anti-tumour activity on its own and increased the effect of gemcitabine. Researchers observed changes in tumour growth, oxidative balance and cancer-cell survival pathways.
These findings are encouraging, but they remain preclinical. They do not prove that the same benefit will occur in people with pancreatic cancer.
The SECAR phase I study investigated intravenous sodium selenite in people with advanced cancers that had continued to progress following previous treatment. The trial examined how the compound moved through the body, what side effects occurred and how much could be administered within the research setting.
Researchers also looked for early signs of anti-cancer activity and possible changes in the response to later chemotherapy. Some responses were observed, but the study was small and did not include a control group. It could not establish whether sodium selenite improved outcomes.
These studies place sodium selenite in an intriguing but still experimental position. It can directly damage cancer cells in laboratory models and may also help sensitise them to other treatments. Its clinical value, however, remains uncertain.
It is equally important not to assume that increasing oxidative pressure is always beneficial.
The effects may depend on the cancer type, the medicine being used, the timing of each intervention and the condition of healthy tissues. A compound might strengthen one treatment, increase toxicity with another or interfere with the intended effect if placed at the wrong time.
Cancer care is not improved by simply adding every promising compound into the same protocol. The biological purpose, sequence and relationship between interventions matter.
Nutritional Selenium and Sodium Selenite Are Different Strategies
One of the most common misunderstandings is the idea that all forms of selenium can be used in the same way.
They cannot.
The first consideration is whether the body has enough selenium to support normal functions. Selenium is needed for thyroid health, immunity and the production of protective enzymes. Correcting a genuine deficiency may therefore be important.
The second consideration is very different: whether sodium selenite might be used for its redox activity to place pressure on cancer cells.
These are not the same objective.
Selenium-rich foods, selenomethionine, selenium yeast and sodium selenite follow different pathways inside the body. They cannot be expected to produce the same effect simply because they all contain selenium.
At nutritional levels, selenium can support the production of antioxidant enzymes, including glutathione peroxidases and thioredoxin reductases. These enzymes help protect cells from oxidation.
That protection may be helpful when supporting normal physiology or correcting deficiency. It is not the same as using pharmacological sodium selenite in an attempt to increase oxidative stress inside a tumour.
This means selenium can appear on both sides of the redox conversation.
In one setting, selenium supports antioxidant defence. In another, sodium selenite may act as a pro-oxidant and place those defences under pressure.
This is not contradictory. It reflects the importance of chemical form, amount, timing and purpose.
The useful question is not simply whether selenium is good or bad. It is:
Which form is being considered?
What job is it intended to perform?
When is it being used?
What other treatments are occurring at the same time?
Without those details, the word “selenium” tells us very little.
What the Evidence Shows—and What It Does Not
Sodium selenite has a substantial amount of laboratory research behind it.
Across many cancer-cell models, it has been shown to increase reactive oxygen species, disturb glutathione balance, interact with the thioredoxin system, damage mitochondria, slow cell division and trigger several forms of cell death.
This gives sodium selenite strong biological plausibility. In other words, there is a well-supported scientific explanation for how the compound may damage cancer cells.
Animal studies provide another layer of evidence. Some have shown reduced tumour growth or increased sensitivity to chemotherapy and radiotherapy.
Animal research gives us more information than a cell dish because it includes blood circulation, metabolism, immune responses and healthy tissues. However, animals and humans do not always process compounds in the same way, and cancers created in laboratory animals do not capture the full complexity of cancer in people.
Human evidence remains limited.
Early phase clinical trials have explored safety, tolerability, pharmacokinetics and combination use. These trials help establish whether a compound can be studied further and what risks may be involved. They are not designed to provide a final answer about survival or long-term tumour control.
Large randomised trials have not yet shown that sodium selenite improves overall survival.
Several important questions therefore remain unanswered. We do not yet know which cancer types are most likely to respond, which tumour characteristics predict sensitivity, how treatment should be timed or whether sodium selenite can consistently target cancer cells without causing unacceptable harm to healthy tissues.
This does not mean the compound has no value. It tells us where it currently sits on the evidence ladder.
Sodium selenite is no longer just a theoretical idea. Its mechanisms have been studied extensively in laboratory models, anti-cancer activity has been demonstrated in animals, and early human trials have taken place.
However, it has not yet become an established cancer treatment.
The most responsible position is neither to dismiss it nor to exaggerate it. It is to remain interested, informed and clear about what is known and what is still being investigated.
What Sodium Selenite Teaches Us About Metabolic Oncology
Sodium selenite matters not only because of what it may do, but because of what it teaches us about cancer.
Cancer cells do not merely need fuel. They also need to survive the consequences of using that fuel.
A rapidly growing cancer cell must produce energy, copy DNA, manufacture proteins, build membranes and constantly adapt to changing conditions. All of this activity creates chemical stress.
The faster the cell operates, the more dependent it may become on systems that control oxidation, repair damage and restore balance.
That dependence can become a weakness.
Sodium selenite does not simply try to deprive the cancer cell of glucose or another nutrient. It may make it harder for the cell to survive the oxidative burden created by its own metabolism.
This is an important shift in thinking.
A metabolic oncology strategy does not ask only what a cancer cell consumes. It also asks how the cell manages the consequences of that consumption, what protects it from damage and whether those protections can be weakened at the right time.
This is what gives sodium selenite its distinctive place in the strategy. It may contribute to the oxidative storm while also interfering with the cancer cell’s umbrella.
Behind that metaphor is a serious biological principle: cancer may be placed under pressure not only by creating more damage, but by reducing its ability to recover from that damage.
This also helps explain why a comprehensive strategy may include several interventions that appear unrelated at first.
One may reduce insulin signalling. Another may restrict a nutrient that the cancer depends upon. Another may interfere with mitochondrial flexibility. Another may support immune recognition. Another may create oxidative pressure, while something else weakens the systems responsible for containing it.
The strength of the strategy does not come from having the longest possible list. It comes from each element having a clear purpose and those purposes being coordinated.
A well-designed protocol should not resemble a kitchen drawer filled with miscellaneous supplements. It should resemble an orchestra. Each instrument has a different role, and the value comes from how they are arranged and when they are played.
Sodium selenite is one of the sharper instruments in that orchestra. Its proposed role is not gentle nutritional background support. It is to apply redox pressure, disturb protection and potentially make a carefully timed pulse more difficult for the cancer cell to survive.
Clinical Perspective and Important Boundaries
The scientific interest surrounding sodium selenite must be balanced with respect for its risks.
Selenium has a relatively narrow window between biological activity and toxicity. Excessive exposure can cause digestive symptoms, fatigue, neurological effects, changes to hair and nails, and injury to the liver, kidneys and other tissues.
This is another reason sodium selenite should not be approached as an ordinary antioxidant supplement.
Its use raises several important questions. Could it make the tumour more sensitive to treatment? Could it also increase damage to healthy tissue? Could a different form of selenium strengthen antioxidant enzymes and work against the intended oxidative pulse? Does liver or kidney function change how the compound is processed? Are other medicines or supplements influencing glutathione, thioredoxin or oxidative stress?
These questions cannot be answered by knowing the name of the compound alone.
The diagnosis, current treatment, organ function, nutritional status, medications and wider protocol all matter. Pharmacological sodium selenite should therefore only be explored with appropriate medical oversight and in communication with the treating oncology team.
It should not be presented as a replacement for surgery, radiotherapy, chemotherapy, immunotherapy or targeted therapy. Its most credible position at present is as an investigational redox-modifying compound that may prove useful within carefully selected combinations.
Sodium selenite is one of the most interesting compounds being explored within metabolic oncology because it appears capable of applying pressure to a central cancer-cell vulnerability from two directions.
As it is processed inside the cell, it may contribute to the production of reactive oxygen species, particularly within the mitochondria. At the same time, it can place demand on glutathione, thioredoxin and other systems needed to control oxidative damage.
This creates its defining double action:
it may increase the oxidative burden while weakening the cancer cell’s ability to carry it.
Laboratory research has shown that this loss of balance can damage mitochondria, disrupt DNA and proteins, and trigger apoptosis, ferroptosis and other forms of cell death. Animal research provides further support, while early clinical studies show that sodium selenite can be investigated alongside cancer treatment under controlled conditions.
What has not yet been established is whether sodium selenite consistently improves survival or tumour control in larger groups of people. It remains investigational and must be approached with both curiosity and caution.
Its greatest value may lie not only in the compound itself, but in the way it helps us think about cancer.
Cancer treatment is not simply a search for something powerful enough to strike the tumour. It is also an attempt to understand what the cancer depends upon, what protects it and whether those protections can be removed at the moment they are needed most.
Within a Press–Pulse strategy, sodium selenite may be understood as a redox-active pulse or pulse sensitiser. Its purpose is to increase pressure at a carefully chosen time and make adaptation more difficult.
Understanding that purpose changes the way a protocol is seen. It is no longer a collection of unexplained tablets, supplements and treatments. Each element begins to reveal its role, its evidence, its limitations and its relationship to the wider strategy.
Agency does not mean independently prescribing treatment or trying to become your own oncologist. It means understanding the reasoning, asking better questions and becoming an informed participant in the decisions surrounding your care.
Sodium selenite may have been named after the Moon, but its importance in cancer research lies in something very grounded: the possibility of turning one of cancer’s own survival mechanisms against it.
.
Important Disclaimer
This article is provided for educational and informational purposes only. It is intended to help you better understand the science, research and possible role of sodium selenite within a broader metabolic oncology approach. It is not medical advice, does not replace individual assessment, and should not be used to diagnose, treat, prescribe or make changes to your cancer care.
Sodium selenite is a biologically active compound with potential risks, interactions and a relatively narrow margin between therapeutic activity and toxicity. Its suitability depends on many factors, including your diagnosis, cancer type, stage of disease, current treatments, medications, supplements, organ function, nutritional status and overall health.
Do not begin, stop or alter any medication, supplement, treatment or oncology protocol based on this article alone. Any consideration of sodium selenite or other metabolic oncology interventions should be discussed with your treating oncology team and guided by a qualified and experienced practitioner in metabolic oncology who can assess your individual circumstances and coordinate care safely.
The research discussed in this article includes laboratory, animal and early clinical evidence. These forms of evidence are not equivalent, and promising mechanisms do not guarantee benefit in an individual case. Cancer care should always remain personalised, evidence-informed and appropriately supervised.
References
Royal Society of Chemistry. Celebrating 200 years of selenium research. Royal Society of Chemistry; 2017.
Royal Society of Chemistry. Selenium: element information, properties and uses. Periodic Table.
Misra S, Boylan M, Selvam A, Spallholz JE, Björnstedt M. Redox-active selenium compounds—from toxicity and cell death to cancer treatment. Nutrients. 2015;7(5):3536–3556. doi:10.3390/nu7053536.
Selenius M, Rundlöf AK, Olm E, Fernandes AP, Björnstedt M. Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxidants & Redox Signaling. 2010;12(7):867–880. doi:10.1089/ars.2009.2884.
Arner ESJ, Holmgren A. The thioredoxin system in cancer. Seminars in Cancer Biology. 2006;16(6):420–426. doi:10.1016/j.semcancer.2006.10.009.
Spallholz JE. On the nature of selenium toxicity and carcinostatic activity. Free Radical Biology and Medicine. 1994;17(1):45–64.
Wallenberg M, Misra S, Wasik AM, et al. Selenium induces a multi-targeted cell death process in addition to ROS formation. Journal of Cellular and Molecular Medicine. 2014;18(4):671–684. doi:10.1111/jcmm.12214.
Shen HM, Yang CF, Ong CN. Sodium selenite-induced oxidative stress and apoptosis in human hepatoma HepG2 cells. International Journal of Cancer. 1999;81(5):820–828. doi:10.1002/(SICI)1097-0215(19990531)81:5<820::AID-IJC23>3.0.CO;2-F.
Shen HM, Yang CF, Ding WX, Liu J, Ong CN. Superoxide radical-initiated apoptotic signalling pathway in selenite-treated HepG2 cells: mitochondria serve as the main target. Free Radical Biology and Medicine. 2001;30(1):9–21. doi:10.1016/S0891-5849(00)00421-4.
Shen HM, Yang CF, Ong CN. Dual role of glutathione in selenite-induced oxidative stress and apoptosis in human hepatoma cells. Free Radical Biology and Medicine. 2000;28(7):1115–1124. doi:10.1016/S0891-5849(00)00206-9.
Li J, Zuo L, Shen T, Xu CM, Zhang ZN. Induction of apoptosis by sodium selenite in human acute promyelocytic leukaemia NB4 cells: involvement of oxidative stress and mitochondria. Journal of Trace Elements in Medicine and Biology. 2003;17(1):19–26. doi:10.1016/S0946-672X(03)80040-2.
Xiang N, Zhao R, Zhong W. Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer Chemotherapy and Pharmacology. 2009;63(2):351–362. doi:10.1007/s00280-008-0745-3.
Huang F, Nie C, Yang Y, et al. Selenite induces redox-dependent BAX activation and apoptosis in colorectal cancer cells. Free Radical Biology and Medicine. 2009;46(8):1186–1196. doi:10.1016/j.freeradbiomed.2009.01.026.
Ganther HE. Reduction of the selenotrisulfide derivative of glutathione to a persulfide analogue by glutathione reductase. Biochemistry. 1971;10(22):4089–4098. doi:10.1021/bi00798a013.
Kumar S, Björnstedt M, Holmgren A. Selenite is a substrate for calf-thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. European Journal of Biochemistry. 1992;207(2):435–439. doi:10.1111/j.1432-1033.1992.tb17070.x.
Tobe R, Yoo MH, Fradejas N, et al. Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism. Biochemical Journal. 2012;445(3):423–430. doi:10.1042/BJ20120244.
Subburayan K, Thayyullathil F, Pallichankandy S, Cheratta AR, Galadari S. Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite. Translational Oncology. 2020;13(11):100843. doi:10.1016/j.tranon.2020.100843.
Choi JA, Lee H, Park JS, et al. High-dose selenium induces ferroptotic cell death in ovarian cancer. International Journal of Molecular Sciences. 2023;24(3):2464. doi:10.3390/ijms24032464.
Chan LS, Lo CY, Wong CM, et al. Selenite as a dual apoptotic and ferroptotic agent synergises with targeted therapy in lung cancer. Scientific Reports. 2023;13:3437. doi:10.1038/s41598-023-30594-x.
Sanmartín C, Plano D, Sharma AK, Palop JA. Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy. International Journal of Molecular Sciences. 2012;13(8):9649–9672. doi:10.3390/ijms13089649.
Zhao S, et al. Docosahexaenoic acid coordinating with sodium selenite promotes paraptosis in colorectal cancer cells by disrupting redox homeostasis and activating the MAPK pathway. Nutrients. 2024;16(11):1690. doi:10.3390/nu16111690.
Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell. 2006;10(3):241–252. doi:10.1016/j.ccr.2006.08.009.
Doello K, Mesas C, Quiñonero F, et al. The antitumour activity of sodium selenite alone and in combination with gemcitabine in pancreatic cancer: an in vitro and in vivo study. Cancers. 2021;13(15):3906. doi:10.3390/cancers13153906.
Brodin O, Eksborg S, Wallenberg M, et al. Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: the SECAR study. Nutrients. 2015;7(6):4978–4994. doi:10.3390/nu7064978.
Knox SJ, Jayachandran P, Keiser J, et al. Results from a phase 1 study of sodium selenite in combination with palliative radiation therapy in patients with metastatic cancer. Translational Oncology. 2019;12(11):1525–1531. doi:10.1016/j.tranon.2019.08.009.
Jayachandran P, Knox SJ, Garcia-Cremades M, et al. Clinical pharmacokinetics of oral sodium selenite and dosing implications in the treatment of patients with metastatic cancer. Drugs in R&D. 2021;21(2):193–202. doi:10.1007/s40268-021-00341-0.
Evans SO, Khairuddin PF, Jameson MB. Optimising selenium for modulation of cancer treatments. Anticancer Research. 2017;37(12):6497–6509. doi:10.21873/anticanres.12114.
Weekley CM, Harris HH. Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease. Chemical Society Reviews. 2013;42(23):8870–8894. doi:10.1039/C3CS60272A.